| Patent Number |
Title Of Patent |
Date Issued |
| 4908470 |
Process for the methyl-4-(dimethylamino)-3,5-dimethoxybenzoate |
March 13, 1990 |
| Methyl 4-dimethylamino-3,5-dimethoxybenzoate, an intermediate in the preparation of the antibacterially active aditoprim, is obtained from 4-amino-3,5-dibromobenzoic acid by replacement of the bromine atoms by methoxy groups and subsequent methylation. |
| 4906626 |
Method of use for treatment or prevention of cognitive disorders |
March 6, 1990 |
| p-Chloro-N-(2-morpholinoethyl)benzamide is capable of counteracting cognitive disorders and can accordingly be used in the treatment or prevention of cognitive disorders, especially of those which are caused by old age. |
| 4900859 |
Process for 4-dimethylamino-3,5-dimethoxybenzaldehyde |
February 13, 1990 |
| 4-Dimethylamino-3,5-dimethoxy-benzaldehyde, an intermediate for the preparation of the antibacterially active aditoprim (4-dimethylamino-3,5-dimethoxybenzoldehyde) a known antibacterially active compound, is obtained from 4-dimethylaminobenzonitrile by bromination or chlorination, re |
| 4898855 |
Deuterated analogs of 1,25-dihydroxycholecalciferol |
February 6, 1990 |
| The invention is directed to deuterated vitamin D analogs, and processes and intermediates for their preparation. The end products, that is the deuterated vitamin D analogs, are useful for the treatment osteoporosis and cutaneous inflammations such as psoriasis, and contact dermatitis. |
| 4896947 |
Liquid crystal display cell |
January 30, 1990 |
| A liquid crystal display (LCD) cell comprising a twist nematic liquid crystal disposed between two electrode plates and polarizers and having a positive dielectric anisotropy. The optical path difference .DELTA.n.d is 0.2 to 0.7 .mu.m. The absolute value of the twist angle .phi. can be |
| 4892886 |
Phenoxypropanolamines |
January 9, 1990 |
| [p-[2-[[(S)-2-hydroxy-3-phenoxypropyl]amino]-ethyl]phenoxy]acetic acid and its physiologically compatible salts, which have catabolic activity and can be used for the treatment of obesity, of diabetes and of conditions which are associated with increased protein breakdown or as feed addi |
| 4889854 |
Tricyclic pyridone derivatives |
December 26, 1989 |
| The compounds of the formula ##STR1## wherein Ra, Rb, Rc, Rd, Re and Rf are as hereinafter described, compounds of formula A which have one or more basic substituents are described and have valuable pharmacological properties. In particular, they have muscle relaxant, sedative-hy |
| 4883791 |
25S,26-dihydroxycholecalciferol in the treatment of hypercalcitriolemic disease states |
November 28, 1989 |
| The invention is directed to a method in the treatment of hypercalcitriolemic disease states which comprises administering an effective amount of 25S,26-dihydroxycholecalciferol to a host in need of such treatment. |
| 4883614 |
Phenyl substituted-2,4,6,8-nonatetraenoic acid |
November 28, 1989 |
| The compounds 9-phenyl-3,7-dimethyl-2,4,6,8 nonatetraenoic acids wherein the phenyl group is substituted with an alkyl, aminoalkyl, hydroxyalkyl, alkoxy, hydroxyalkylamino, and a hydroxy alkoxy group, and derivatives thereof which are used as disease modifying anti-rheumatic agents and a |
| 4881993 |
Explosive and propellant composition and method of preparation |
November 21, 1989 |
| The carbonyl compounds 5,6-carbonyl-ascorbic acid and 5,6-carbonyl-erythorbic acid been found useful for the preparation of explosive and propellant materials by admixing them with nitrate-containing oxidation agents and optionally further ingredients. |
| 4866205 |
Prostaglandin intermediates |
September 12, 1989 |
| New optically active intermediates and processes thereto are provided for use in synthesizing therapeutically active prostaglandins of the formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; from a compound of the formula: ##STR2## wherein R.sup.1 is as above and R. |
| 4866205 |
Prostaglandin intermediates |
September 12, 1989 |
| New optically active intermediates and processes thereto are provided for use in synthesizing therapeutically active prostaglandins of the formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; from a compound of the formula: ##STR2## wherein R.sup.1 is as above and R. |
| 4859306 |
Selectively ion-permeable dry electrodes for analyzing selected ions in aqueous solution |
August 22, 1989 |
| The electrode comprises an internal reference half-cell at stable potential comprising a conductive sheet, e.g. of metal of carbon, covered by a redox system. The redox system comprises a thin dehydrated layer of Prussian blue deposited by contact between the sheet and a mixture of alkal |
| 4855297 |
Tricyclic pyridone derivatives |
August 8, 1989 |
| The compounds of the formula ##STR1## wherein Ra,R.sub.b,R.sub.c R.sub.d are defined in the specification and pharmaceutically acceptable addition salts are disclosed.The compounds of formula I have valuable pharmacological properties and can be used for the control or prevention of |
| 4837311 |
Anti-retroviral compounds |
June 6, 1989 |
| A-B-C wherein A and C are each independently 2',3' dideoxynucleosides and B is a linking group; and a method of treating or preventing a retroviral injection in a subject by administering the compounds of the invention. |
| 4824971 |
2-allylchromans |
April 25, 1989 |
| Novel 2-halochromans and their coupling to various nucleophiles to produce Vitamin E and as well as novel intermediates for Vitamin E. |
| 4816581 |
4-(phenylthio or phenylsulfonyl) azetidinones and process of manufacture |
March 28, 1989 |
| The novel compounds of the formula ##STR1## wherein R.sup.11 signifies hydrogen, acyl or tri(lower alkyl)silyl, R.sup.2 signifies a phenyl group which is substituted in the o- and/or the p-position by halogen, lower alkyl, lower alkylthio or lower alkoxy and n signifies the numbe |
| 4814332 |
Antimicrobial 1,3-disubstituted/imidazolium salts |
March 21, 1989 |
| The imidazolium compounds of the formula ##STR1## wherein the various substituents are defined hereinbelow and their pharmaceutically acceptable acid addition salts, which possess valuable pharmacological properties are described. In particular, they possess antibacterial, antimy |
| 4808713 |
Anthypertensive pyridazo [1,2-a][1,2]diazepines |
February 28, 1989 |
| Novel compounds of the formula ##STR1## wherein B represents a methylene, ethylene or vinylene group, R.sup.1 represents a hydrogen atom or an alkyl, aralkyl, amino-alkyl, mono-alkylamino-alkyl, dialkylamino-alkyl, acylamino-alkyl, phthalimido-alkyl, alkoxycarbonylamino-alkyl, ar |
| 4801704 |
Methylene penam and derivatives thereof |
January 31, 1989 |
| There are presented compounds of the formula ##STR1## wherein R.sub.2, R.sub.3, R.sub.4 and m are as described herein. |
| 4792557 |
2,4-diamino-5[4-amino (or dimethylamino)-3,5-dimethoxybenzyl]pyrimidine and antibacterial compos |
December 20, 1988 |
| 2,4-Diamino-5-benzylpyrimidines of the formula ##STR1## wherein R.sup.1, R.sup.2, A, Z and n are as hereinafter set forth, are described. The 2,4-diamino-5-benzylpyrimidines of the invention have useful antibacterial activity. More particularly, they inhibit bacterial dihydrofola |
| 4789750 |
2-(trimethyl-tridecenyl)-tetramethylchroman intermediates for vitamin E |
December 6, 1988 |
| 6-Etherified hydroxy -2-(4',8',12'-trimethyl-5'-tridecenyl)-2,5,7,8-tetramethylchromans with an oxo or hydroxy substituent at the 2' position which may be substituted with an arylsulfonyl or a carboxyalkyl at the 3' position and containing a single or double bond at the 11 position, |
| 4788214 |
3,4-dihydro-2H-1-benzopyran derivatives |
November 29, 1988 |
| The invention relates to compounds of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkyl; R.sup.2 is hydrogen or halogen; R.sup.3, R.sup.4 and R.sup.5 are hydrogen, acyl or lower alkyl; R.sup.6 and R.sup.7, independently, are hydrogen or lower alkyl; X is alkylene.su |
| 4788213 |
Benzopyranyl and benzothiopyranyl compounds and uses |
November 29, 1988 |
| Novel p-[2(4,4-dimethyl-6-heterophenyl)substituted phenyl derivatives and salts thereof which are useful for combatting neoplasms and dermatoses including oral and topical compositions containing said derivatives which are suitable for such uses. |
| 4782149 |
Pyridazodiazepine derivatives |
November 1, 1988 |
| Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 each independently represent hydrogen, C.sub.1 -C.sub.10 -alkyl, adamantyl-(C.sub.1 -C.sub.4 -alkyl) or (C.sub.2 -C.sub.6 -alkanoyloxy)-(C.sub.1 -C.sub.4 -alkyl), and pharmaceutically acceptable salts thereof possess a |
| 4780251 |
Phenyl substituted-2,4,6,8-nonatetraenoic acid |
October 25, 1988 |
| The compounds 9-phenyl-3,7-dimethyl-2,4,6,8-nonatetraenoic acids wherein the phenyl group is substituted with an alkyl, aminoalkyl, hydroxyalkyl, alkoxy, hydroxyalkylamino, and a hydroxy alkoxy group, and derivatives thereof which are used as disease modifying anti-rheumatic agents and a |
| 4766133 |
(Bezimidazol-2-yl)-pyridinium compounds |
August 23, 1988 |
| (Benzimidazol-2-yl)-pyridinium compounds of the formula ##STR1## wherein A is --SR.sup.9, --SO.sub.3.sup.- or --S--SO.sub.3.sup.- ; R.sup.1 and R.sup.3 each is hydrogen or (C.sub.1 -C.sub.7)-alkyl; R.sup.2 is hydrogen, (C.sub.1 -C.sub.7)-alkyl, (C.sub.1 -C.sub.7)-alkoxy or a neg |
| 4731373 |
Glycerin derivatives and inhibition of blood PAF |
March 15, 1988 |
| Glycerine derivatives of the formula ##STR1## wherein the residues R.sup.1, R.sup.2 and R.sup.3 have the significance given in the description,and their hydrates, which inhibit blood platelet activating factor (PAF), are descried. |
| 4720546 |
Intermediates for the preparation of substituted 2-phenyl-1,3-dioxolanes |
January 19, 1988 |
| The compounds of the formula ##STR1## wherein one of the symbols Q and Q' is the group --CH.dbd. and the other is the group --CH.dbd. or --N.dbd., R.sup.1, R.sup.2 and R.sup.3 each independently are hydrogen or halogen and n is the integer 0, 1 or 2, and their pharmaceutically ac |
| 4716148 |
Prothymosin alpha |
December 29, 1987 |
| A new biological polypeptide hormone has been isolated from mammalian thymus and has been given the designation prothymosin alpha. This peptide contains approximately 107 to 113 amino acid residues depending on species and is distinguished by having the thymosin alpha.sub.1 sequence at i |
| 4711889 |
Schistosomicidal acridanone hydrazones |
December 8, 1987 |
| The invention relates to acridanone derivatives of the formula ##STR1## wherein the dotted line is an optional bond, R.sup.1 is hydrogen, halogen or nitro,R.sup.2 is hydrogen or lower alkyl,one of R.sup.3 and R.sup.4 is hydrogen or lower alkyl and the other together with R is an addi |
| 4708441 |
Esters |
November 24, 1987 |
| Compounds of the formula ##STR1## wherein X.sup.2 is a single covalent bond or --COO--; X.sup.1 is a single covalent bond, --COO--, --CH.sub.2 CH.sub.2 -- or when X.sup.2 is --COO--, X.sup.1 also can be p--C.sub.6 H.sub.4 --, p--C.sub.6 H.sub.4 --CH.sub.2 CH.sub.2 --, --CH.sub.2 |
| 4689350 |
Treatment of dermatoses and illnesses producing inflammation |
August 25, 1987 |
| 1,2,3,4-Tetrahydro-1,1,4,4-tetramethyl-6-(alpha-methylstyryl)naphthalene possesses antikeratinizing, antiinflammatory and immunomodulatory properties and can be used in the treatment or prevention of dermatoses which are accompanied by a pathological cornification as well as inflamma |
| 4681756 |
Prevention of N-nitroso compound formation in vivo |
July 21, 1987 |
| The effect of a controlled release, hydrodynamically balanced dosage formulation containing both an aqueous phase N-nitroso compound blocking agent and a lipid phase N-nitroso compound blocking agent in preventing the formation of nitrosamines and nitrosamides in the stomach is discl |
| 4678790 |
Certain .alpha.-benzyl-3-pyridylmethanols, N-oxides thereof and their fungicidal use |
July 7, 1987 |
| Novel pyridine, pyrazine and pyrimidine derivatives of the formula ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as hereinafter set forth, and acid addition salts thereof, processes for their preparation, fungicidal compositions containing these compounds as the activ |
| 4670247 |
Process for preparing fat-soluble vitamin active beadlets |
June 2, 1987 |
| A process is described for the preparation of fat-soluble vitamin active beadlet compositions which exhibit superior stability when exposed to the feed pelleting process. The process includes forming an aqueous emulsion of a fat-soluble vitamin-active material, gelatin, and a sugar conve |
| 4663470 |
Alpha-tocopherol intermediates |
May 5, 1987 |
| A novel process for the manufacture of quinone derivatives which are suitable as intermediates for the manufacture of (2RS,4'R,8'R)-tocopherol is described. In this process a quinone of the formula ##STR1## is reacted with a phytyl derivative of the formula ##STR2## If desire |
| 4663469 |
4-hydroxy-l-threoninamides |
May 5, 1987 |
| A novel enantiomeric systhesis from ascorbic acid of (3S,4S)-3-amino-4-carbamoyloxymethyl-2-azetidinone-1-sulfate, an intermediate for an antibiotic compound. |
| 4663332 |
5-substituted N-alkylated tetrazoles |
May 5, 1987 |
| Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and A are as described herein, are set forth.These compounds are useful as anti-allergic agents and agents for the treatment of cardiovascular diseases. |
| 4652405 |
Synthesis of 1.alpha.,25-dihydroxy-24R-fluorocholecalciferol and 1.alpha.,25-dihydroxy-24S-fluor |
March 24, 1987 |
| 1.alpha.,25-Dihydroxy-24R-fluorocholecalciferol and 1.alpha.,25-dihydroxy-24S-fluorocholecalciferol, analogs of 1.alpha.,25-dihydroxy-cholecalciferol which is physiologically the most active metabolite of vitamin D.sub.3, are synthesized in a multistep process from the known substanc |
| 4594442 |
Naphthalenyloxy substituted carboxylic acids |
June 10, 1986 |
| Compounds of the formula ##STR1## wherein R is hydrogen or lower alkyl, X is hydrogen or halogen, and A is the group ##STR2## wherein R.sub.1 is hydrogen, acyl or lower alkyl, R.sub.2 is hydrogen or lower alkyl, m is an integer from 2 to 4, n is an integer from 1 to 3, and |
| 4594432 |
Process for the synthesis of 1.alpha.,23(S),25-trihydroxycholecalciferol and 1.alpha.,23(R),25-t |
June 10, 1986 |
| The invention is directed to a process and intermediates for the preparation of 1.alpha.,23(S),25-trihydroxycholecalciferol and 1.alpha.,23(R),25-trihydroxycholecalciferol. The end-products, 1.alpha.,23(S),25-trihydroxycholecalciferol and 1.alpha.,23(R),25-trihydroxycholecalciferol, |
| 4579973 |
Process for the manufacture of cyclohexene derivatives |
April 1, 1986 |
| A novel process for the manufacture of cyclohexene derivatives which are suitable as intermediates for the manufacture of rhodoxanthin or zeaxanthin, as well as a process for the manufacture of rhodoxanthin or of zeaxanthin itself. The invention is also concerned with a novel starting |
| 4578475 |
Novel D-homosteroids |
March 25, 1986 |
| The novel D-homosteroids of the formula ##STR1## wherein R.sup.1 represents a --CN, .dbd.NOH or .dbd.CH--NHOH group; R.sup.2 represents oxo or, where R.sup.1 represents a --CN group, R.sup.2 represents oxo or a --OAc group; or R.sup.1 and R.sup.2 together with carbon atoms 2 and |
| 4576751 |
.beta.-Lactams |
March 18, 1986 |
| There is presented optically uniform .beta.-lactams of the formulae ##STR1## wherein Z is a readily cleavable acyl group, R.sup.1 is amino or a group convertible into amino, R.sup.2 is hydrogen or a readily cleavable protecting group and R.sup.3 and R.sup.4 each are a lower hydrocarb |
| 4544659 |
Schistosomicidal acridanone hydrazones |
October 1, 1985 |
| Acridanone derivatives of the formula ##STR1## wherein the dotted line is an optional bond, R.sup.1 is hydrogen, halogen or nitro, R.sup.2 is hydrogen or lower alkyl, one of the substituents R.sup.3 and R.sup.4 is hydrogen or lower alkyl and the other together with R is an additi |
| 4504415 |
Synthesis of thymosin .alpha..sub.1 and desacetyl thymosin .alpha..sub.1 |
March 12, 1985 |
| An improved solution phase synthesis of thymosin .alpha..sub.1 and desacetyl thymosin .alpha..sub.1 with t-Boc side chain protection and proceeding through novel intermediates is disclosed. |
| 4483990 |
Preparation of diketones |
November 20, 1984 |
| The preparation of bicyclic diketones of the formula ##STR1## wherein R.sub.1 is lower alkyl or ar-lower alkyl, from compounds of the formula ##STR2## wherein R.sub.1 is as set forth above, is described. |
| 4472574 |
Process for the manufacture of a cephem carboxylic acid derivative |
September 18, 1984 |
| A process is disclosed for the manufacture of (7R,8R)-7-amino-3-[[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-as-triazin-3-yl) -thio]-methyl]-3-cephem-4-carboxylic acid by reacting (7R, 8R)-7-amino-cephalosporanic acid with 2,5-dihydro-6-hydroxy-3-mercapto-2-methyl-5-oxo-as-triazine in the |
| 4472435 |
Benzophenone derivatives useful in treating heart failure |
September 18, 1984 |
| There is presented novel benzophenone derivatives of the formula ##STR1## wherein R.sup.1 is hydrogen or lower alkyl, R.sup.2 is hydrogen or aminoacetyl, R.sup.3 is hydrogen or lower alkyl, R.sup.4 is hydrogen or halogen, R.sup.5 is hydrogen, amino, nitro or a group of the formula |
